



**(301) 366-4841**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 8, 2013 Neuralstem, Inc. (the “Company”) announced that Eva Feldman, MD, PhD, and principal investigator of the Company’s Phase II trial using NSI-566 for the treatment of amyotrophic lateral sclerosis will be a guest on Sirius XM’s Doctor Radio station, channel 81, on Thursday, May 9, 10-11am EDT. A copy of the press release is attached to this report as Exhibit 99.01.

It is anticipated that Richard Garr, the Company’s CEO, will be providing commentary via the Company’s social media channels.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 8.01. Other Events.**

Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use the following social media channels as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD:

• Neuralstem’s Twitter Account ([https://twitter.com/Neuralstem\\_Inc](https://twitter.com/Neuralstem_Inc))

• Neuralstem’s Facebook Page (<https://www.facebook.com/Neuralstem>)

• Neuralstem’s Company Blog (<http://neuralstem.com/neuralstem-ceo-blog>)

• Neuralstem’s Google+ Page

(<https://plus.google.com/u/0/b/104875574397171789280/104875574397171789280/posts>)

• Neuralstem’s LinkedIn Company Page (<http://www.linkedin.com/company/neuralstem-inc->)

The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these accounts and the blog, in addition to following the company's press releases, SEC filings and public conference calls and webcasts. This list may be updated from time to time.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit Number** Description

99.01 Press Release Dated May 8, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr

Chief Executive Officer

Dated: May 9, 2013

**INDEX OF EXHIBITS**

**Exhibit Number** Description

99.01 Press Release Dated May 8, 2013